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The elegant studies conducted in vitro by Chamberlain [1]
demonstrate convincingly that the HMG-CoA reductase in-
hibitor lovastatin, a widely clinically used cholesterol-reducing
drug distributed as Mevacor, also inhibits physiological insu-
lin-stimulated glucose transport. The author postulates that
the mechanism of this e¡ect is via the inhibition of isoprenoid
biosynthesis, another intermediate product of the cholesterol
complex pathway. As expected, this e¡ect was reversed by the
isoprenoid (and cholesterol) precursor mevalonate.
The o¡ered concept that defects in isoprenoid metabolism
can lead to cellular insulin resistance is a major step forward,
with decisive theoretical and clinical consequences. The au-
thor speculates further that the possible intimate mechanism
involves the inhibition of the protein prenylation by farnesol
and geranylgeraniol ^ also intermediates of cholesterol biosyn-
thesis. Yet, another reasonable mechanism, not entertained by
Dr. Chamberlain, is the involvement of one of the end-prod-
ucts of the cholesterol biosynthetic pathway ^ coenzyme Q.
It is now well established that the cholesterol-reducing
drugs known as statins also restrain the biosynthesis of coen-
zyme Q (coenzyme Q10 in humans or ubiquinone), with re-
ported clinical consequences (reviewed in [2,3]). Coenzyme Q
is a vitamin-like, fat-soluble nutrient (a quinone) and func-
tions as a vital component of the mitochondrial energy elec-
tron transduction chain and ATP production, as a powerful
antioxidant, and as a membrane stabilizer. The cardioprotec-
tive, cytoprotective, and neuroprotective clinical potential of
coenzyme Q, and its involvement in the so-called diseases of
bioenergetics, is subject of many publications and internation-
al symposia.
A thesis has been advanced that at least some of the statins’
recognized side e¡ects result from the coenzyme Q10 endoge-
nous biosynthesis suppression, culminating in the develop-
ment of a coenzyme Q10 de¢ciency.
An early study indicates [4] that the coenzyme Q10 blood
level in diabetics is signi¢cantly lower and furthermore, four
antidiabetic drugs tested also lowered this coenzyme Q10 level.
A farsighted interpretation of this observation by the authors
is that coenzyme Q10 de¢ciency in the pancreas could impair
bioenergetics, the generation of ATP, and the biosynthesis of
insulin. Similar conclusions were reached much later by
McCarty [5]. In 2001, Langin published a study substantiating
the link between diabetes, insulin secretion, and the pancreatic
L-cell mitochondrial function. According to the study, mito-
chondrial ATP increase inhibits ATP-sensitive potassium
channels, which in turn stimulates insulin secretion. In the
process of generating ATP, control of the coupling between
oxygen consumption and ATP synthesis is essential, since it
modulates ATP levels [6].
Several lines of evidence strongly suggest that insulin resis-
tance and diabetes type I and II are associated with increased
production of reactive oxygen species, oxidative stress, and
reduced antioxidant defences (reviewed in [7]). It has also
been demonstrated that acute hyperglycemia stimulates the
production of free radicals [7]. For this and other reasons,
the European Association for the Study of Diabetes organized
in 1998 an ‘Expert Session’ on oxidative stress [8]. Fur-
thermore, there are encouraging data pointing to a favor-
able e¡ect in diabetic patients treated with antioxidants ^
vitamins E and C [7,9] and more recently with K-lipoic acid
[9,10].
Studies demonstrating clinical improvement in diabetics
treated with coenzyme Q10 were initiated as early as 1966.
The results of ¢ve early clinical trials, using very low coen-
zyme Q10 doses, were reviewed by Yamamura [11]. In a more
recent study [12], a randomized double-blind, placebo-con-
trolled trial of 62 patients treated with the equivalent of 300
mg/day coenzyme Q10 showed a signi¢cant reduction of their
fasting and postprandial blood glucose and their fasting in-
sulin level, indicating an improved hyperglycemia and insulin
sensitivity. A further thought-provoking topic is a review by
Sinatra [13], which includes a short chapter on the diabetes^
coenzyme Q10 relationship.
The basic and clinical details presented, in part, in this short
synopsis support strongly the biochemical premise o¡ered by
Chamberlain [1], and justify further the organization of larger,
state-of-the-art clinical trials evaluating the coenzyme Q10 role
as an adjunctive treatment for diabetes, alone or in combina-
tion with other antioxidants. Equally consequential will be the
prospective study of the management of the complications
associated with the progression of this debilitating disease,
injuring many compartments of the body, most importantly
the cardiovascular system.
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